NEWS

  • MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS

    Medical Research NewsPublished: Tuesday, 11-Apr-2006 The Myeloproliferative Disorders Foundation has awarded $750,000 to establish the MPD Research Alliance, a collaboration of the University of Illinois at Chicago, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders. The Foundation plans to donate $10 million to the Research Alliance over… Read More »MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS

    READ MORE

    AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF

    An interview with D. Gary Gilliland, PhD, MD Member, Medical Advisory Board, MPD FoundationProfessor of Medicine, Harvard Medical SchoolInvestigator, Howard Hughes Medical InstituteDirector, Leukemia Program, Dana-Farber/Harvard Cancer CenterDirector, Cancer Stem Cell Program, Harvard Stem Cell Institute . IntroductionPositive Identification of the Causal Gene MutationHow Gleevec WorksWhy the Mutation Doesn’t Always Show UpNext Steps in Drug… Read More »AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF

    READ MORE

    MPD GENE MUTATION DISCOVERED!

    After years of searching, a major breakthrough. The first news came out on March 17, 2005: A team of researchers at the Cambridge Institute for Medical Research, UK, led by Dr. Tony Green, announced that they had discovered a single point mutation in the JAK2 gene that appeared in 97% of polycythemia vera patients they… Read More »MPD GENE MUTATION DISCOVERED!

    READ MORE

    STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME

    By Donna Young Washington Editor Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology’s annual meeting in Atlanta. In a retrospective study examining 30 years of records of 311 patients with myelofibrosis,… Read More »STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME

    READ MORE

    NOVARTIS ENTERS INTO PARTNERSHIP WITH INCYTE

    Novartis will collaborate with Incyte on the further development of two of Incyte Corp.’s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis. For more information: Press release BioWorld

    READ MORE

    INCYTE REACHES AGREEMENT WITH FDA ON MF DRUG

    July 22, 2009 The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis. The Special Protocol Assessment (SPA) for the design of the trial is related to reduction in spleen size, a goal Incyte is confident they will… Read More »INCYTE REACHES AGREEMENT WITH FDA ON MF DRUG

    READ MORE

    INCYTE’S SELECTIVE JAK1 / 2 INHIBITOR, INCB18424, DEMONSTRATES RAPID AND DURABLE CLINICAL BENEFITS IN MYELOFIBROSIS PATIENTS – DATA PRESENTED AT ASH ANNUAL MEETING IN SAN FRANCISCO 2008

    WILMINGTON, DE – December 6, 2008 — Incyte Corporation (Nasdaq: INCY) will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting. MF is a serious neoplastic condition characterized by varying degrees… Read More »INCYTE’S SELECTIVE JAK1 / 2 INHIBITOR, INCB18424, DEMONSTRATES RAPID AND DURABLE CLINICAL BENEFITS IN MYELOFIBROSIS PATIENTS – DATA PRESENTED AT ASH ANNUAL MEETING IN SAN FRANCISCO 2008

    READ MORE

    INCYTE’S NOVEL JAK INHIBITOR DEMONSTRATES RAPID CLINICAL BENEFITS IN ONGOING PHASE I/II MYELOFIBROSIS STUDY

    Results Presented June 2, 2008 at the 2008 American Society of Clinical Oncology Annual Meeting WILMINGTON, Del.–(BUSINESS WIRE)–June 2, 2008–Incyte Corporation (Nasdaq: INCY) announced today the presentation of clinical results from a Phase I/II study of INCB18424, its orally available janus-associated kinase (JAK) inhibitor, in patients with myelofibrosis. Myelofibrosis (MF) is a serious neoplastic condition… Read More »INCYTE’S NOVEL JAK INHIBITOR DEMONSTRATES RAPID CLINICAL BENEFITS IN ONGOING PHASE I/II MYELOFIBROSIS STUDY

    READ MORE

    UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT

    By Terri Somers Union-Tribune Staff Writer 9:01 a.m. April 7, 2008 A one-year scientific collaboration that included the University of California San Diego and the tiny local biotechnology company TargeGen has moved a treatment for a potentially fatal blood disease into human trials at record speed. The experimental drug is also the first in clinical… Read More »UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT

    READ MORE

    IMAGO BIOSCIENCES TO EXPAND CLINICAL TRIAL OF IMG-7829 FOR MF PATIENTS

    Presented at the 24th Congress of the European Hematology Association (EHA), Imago BioSciences, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases. “IMG-7289 has… Read More »IMAGO BIOSCIENCES TO EXPAND CLINICAL TRIAL OF IMG-7829 FOR MF PATIENTS

    READ MORE

    1 34 35 36
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?